加拿大卫生部批准CARVYKTI,这是一项新的多种间皮瘤治疗,给病人带来重大好处。 Health Canada approves CARVYKTI, a new multiple myeloma treatment showing significant patient benefits.

加拿大卫生部已批准CARVYKTI治疗曾尝试过1至3次治疗的多位骨髓瘤患者。 Health Canada has approved CARVYKTI for treating patients with multiple myeloma who have tried one to three prior treatments. 这种药物是首个针对该病期的BCMA向治疗,与标准治疗相比,该药物降低了疾病进展或死亡风险74%. The drug is the first BCMA-targeted therapy for this stage of the disease, showing a 74% reduction in the risk of disease progression or death compared to standard treatments. 这一批准是继第三阶段研究取得积极成果之后作出的。 This approval follows positive results from a Phase 3 study.